| Bioactivity | Temelimab (GNbAC-1) is an IgG4 monoclonal antibody that targets the human endogenous retroviral envelope protein HERV-W-Env[1][2]. |
| Invitro | Temelimab 在体内安全且耐受性良好[1]。 |
| Name | Temelimab |
| CAS | 1393641-34-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kornmann G, et, al. Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review. Drug Saf. 2020 Dec;43(12):1287-1296. [2]. Hartung HP, et, al. Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Mult Scler. 2022 Mar;28(3):429-440. |